Management Consulting

Commercial and Vendor Due Diligence

Clear investment analysis and recommendation

Benefit from tailored, complete acquisition insight, investment evaluation and recommendation with our commercial and vendor due diligence. Get in-depth market analysis, competitive landscape and positioning, and business plan assessment from our team of global specialists.

Due diligence designed to meet your business goals

Alira Health delivers analysis and insights to help you clearly assess the benefits and risks of proposed investments with commercial due diligence (CDD) and vendor due diligence (VDD). 

We also conduct careful analysis of biologic product or technology assets for potential partnering or acquisition. When an assessment of CMC aspects of these assets is needed, get technical expertise from our CMC specialists to conduct CMC due diligence to make a well-rounded and informed decision.
By evaluating and forecasting potential outcomes, we’ll help you determine how best to meet your short- and long-term business goals through acquisitions.
We evaluate and prepare companies for:

CDD: Private acquisitions

  • Identification of the target’s sources of competitive advantage
  • Challenges management’s assumptions
  • Verifies top line growth prospects

VDD: Sale or IPO

  • Analysis of its top markets
  • Internal assessment of the firm (Phase I)
  • Ongoing support in the preparation process (Phase II)

Why choose Alira Health?

With Alira Health as your partner, you will benefit from:

  • An experienced team with successful deals worth an accumulated €10B
  • An integrated approach, allowing the team to view assess opportunities from every angle
  • Click here to see how we delivered a recent growth opportunity assessment for a leading pharmaceutical company

Related news

Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Due Diligence Research & Development
News July 21, 2021
Alira Health Announces its Role as Strategic Advisor to Naxicap
Alira Health is proud to announce its role as strategic advisor to Naxicap in the equity investment in Ceres Pharma Bv.
Due Diligence Pharma
Multimedia April 12, 2021
Evolution of the Drug Delivery Systems Industry and its Increasing Role in Driving Patient Outcomes
In the third episode, Amira Ghozali, Aptar Pharma, Kenny Carberry, and Aude Ouensanga, discuss the evolution of the DDS industry, its relationship with Pharma, and its increasing role(...)
Due Diligence MedTech Patient Engagement Pharma
Publications March 24, 2021
Drug Delivery Devices (DDD): Increasing Role in Patient Outcome and Future Trends, New England’s Global Appeal to Foster Collaboration
Download our newest report, Drug Delivery Devices (DDD): Increasing role in patient outcome and future trends, New England’s global appeal to foster collaboration. In this report,(...)
Due Diligence MedTech Patient Engagement
News March 11, 2020
We Announce role as Strategic Advisor to Gener8 on its Acquisition of Symbient
MUNICH, GERMANY – MARCH 11, 2020 – Alira Health, a leading international healthcare and life sciences advisory firm, was selected as the strategic advisor to Gener8 engineering(...)
Due Diligence M&A MedTech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.